READYCELL SL

España

Fabricante/ Productor

Vista previa del catálogo productos

España

24 or 96 transwell insert plates seeded with 21 days differentiated and polarized Caco-2 cells. This cell model is considered to be the gold standard for assessing intestinal permeability of new oral drugs in in vitro preclinical studies, according to leading regulatory agencies.

Pedir presupuesto

España

24 or 96 transwell insert plates cultured with 12 days differentiated MDR1-overexpressing MDCKII cells. The MDR1 efflux transporter has an ubiquitous tissue distribution, with a critical role in intestinal absorption, biliary and urinary excretion of drugs and in the entry of active molecules into the central nervous system.

Pedir presupuesto

España

24 or 96 transwell insert plates cultured with 12 days differentiated BCRP-overexpressing MDCKII cells. BCRP is a high-capacity efflux transporter with broad substrate specificity. It is located in the apical cell membrane of barrier tissues and and excretory organs.

Pedir presupuesto

España

24 transwell insert plates seeded with 21 days differentiated and polarized Caco-2 and HT-29 cells with an absorptive and mucus-secreting phenotype, respectively. This co-culture allows evaluating the in vitro intestinal absorption of drug targets at a barrier physiologically closer to the intestinal epithelium. In addition, their responsiveness to inflammatory mediators provides valuable information on the efficacy of anti-inflammatory drugs.

Pedir presupuesto

Ver todo el catálogo de productos

ReadyCell is a biotechnological company focused on providing superior cell-based in vitro kits for the ADME-Tox market segment. Our innovative products facilitate and streamline drug discovery and medical research studies. All kits include a revolutionary and patented gel-like cell culture medium, Shipping Medium®, which preserves cell functionality and viability at room temperature up to 7 days. The Shipping Medium technology is an ideal option for worldwide shipments. ReadyCell products are developed with a ready-to-use biotechnology, allowing to carry on drug discovery preclinical assays in a clear and straightforward manner. Our specialized biotechnological portfolio offers a complete range of possibilities to evaluate novel molecules pharmacokinetics in preclinical stages, following regulatory recommendations and scientific requirements.